FDA Approves First-Ever Standalone Therapy For Treatment-Resistant Depression
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved standalone treatment for this condition.
Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...
Spravato was previously approved by the FDA in 2019 for treatment-resistant depression, but it was required to be used with an oral antidepressant. The new FDA approval means people can use the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback